Products
Chlorprothixene is commercially available in the form of film-coated tablets (Truxal). It has been approved in many countries since 1960. Distribution of the so-called Truxal 5 mg tablets was discontinued in many countries in 2011 for economic reasons.
Structure and properties
Chlorprothixene (C18H18ClNS, Mr = 315.9 g/mol) belongs to the thioxanthenes. It is present in drugs as chloroprothixene hydrochloride, a white crystalline powder that is soluble in water. It is structurally closely related to chlorpromazine.
Effects
Chlorprothixene (ATC N05AF03) has antipsychotic, antidepressant, antidopaminergic, anticholinergic, antipruritic, antiemetic, and sedative (depressant) properties. The effects are due to antagonism at dopamine and serotonin receptors. Furthermore, chlorprothixene also blocks alpha1-adrenoceptors, histamine H1 and muscarinic acetylcholine receptors. The mean half-life is 15 hours.
Indications
- Schizophrenia.
- Psychosis with psychomotor agitation, anxiety and agitation.
- Mania.
- Anxiety, restlessness and aggressiveness in alcoholics or toxicomaniacs (rehab).
- Agitation, restlessness and anxiety associated with depressive syndromes and neuroses.
- Severe behavioral disorders associated with oligophrenia, such as erethism, agitation.
- As an adjunct to analgesics in severe chronic pain conditions.
Dosage
According to the professional information. The dosage is adjusted individually. Tablets are taken up to three times daily.
Contraindications
For complete precautions, see the drug label.
Interactions
Chlorprothixene is a substrate of CYP2D6 and corresponding drug interactions are possible. Central depressant drugs and anticholinergics may increase depressant and adverse effects. Other interactions may occur with drugs that prolong the QT interval.
Adverse effects
The most common potential adverse effects include drowsiness, dizziness, dry mouth, and increased salivation. Chlorprothixene prolongs the QT interval.
